What are the side effects of IGF-1 LR3?

IGF-1 LR3 vs native IGF-1: why the safety profile does not transfer

Native IGF-1 exists as an approved drug (mecasermin / Increlex, for severe primary IGF-1 deficiency in children). IGF-1 LR3 is a modified analog — an arginine substitution at position 3 and a 13-amino-acid N-terminal extension reduce its binding-protein affinity, extending half-life from minutes to roughly 20–30 hours and raising potency about threefold. Because the analog stays active far longer and is not the approved molecule, IGF-1's clinical adverse-event profile does not automatically describe it — and IGF-1 LR3 itself has no controlled human trials.

Hypoglycemia — the cited adverse effect

The cited pharmacological review of growth hormone, IGF-I, and insulin as anabolic agents documents hypoglycemia as IGF-I's principal adverse effect, driven by its insulin-like action on glucose uptake. Because IGF-1 LR3 retains and prolongs IGF-1 receptor agonism, this is the mechanistically central risk for the analog — and the reason the research convention pairs administration with food, since injected without food the glucose-uptake effect can lower blood sugar.

The cancer / mitogenic question

IGF-1 is a growth factor: the cited mechanism studies show IGF-1 LR3 drives cell proliferation through the PI3K/Akt and MAPK/ERK pathways. That mitogenic action is the basis for a theoretical concern — whether it could accelerate the growth of a pre-existing tumor. The cited literature does not resolve this: those studies characterized muscle, bone, and signalling mechanisms, not cancer outcomes, and no cited trial measured malignancy risk in humans. The question is open, not answered, in the sources this profile cites.

What is not established

Other effects discussed in the research community — joint pain, fluid retention, carpal-tunnel-like numbness, and receptor desensitization with sustained high-dose use — are not characterized in the cited literature. They are reported anecdotally rather than measured in a trial of the analog, and no completed human safety study of IGF-1 LR3 exists to confirm or rule them out.

• Hypoglycemia is the one adverse effect the cited literature supports (IGF-1's insulin-like glucose-uptake action).
• IGF-1 LR3 has no controlled human trials; native IGF-1's approved-drug profile does not transfer automatically.
• The mitogenic mechanism is cited; the human cancer-risk question is not resolved by the cited sources.
• Other reported effects are anecdotal, not characterized in the cited literature.